Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $215.00 billion. The enterprise value is $225.68 billion.
| Market Cap | 215.00B |
| Enterprise Value | 225.68B |
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Aug 18, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.46% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.46% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 29.52% |
| Float | 3.19B |
Valuation Ratios
The trailing PE ratio is 12.97 and the forward PE ratio is 13.10.
| PE Ratio | 12.97 |
| Forward PE | 13.10 |
| PS Ratio | 4.34 |
| Forward PS | 0.62 |
| PB Ratio | 8.06 |
| P/TBV Ratio | 21.62 |
| P/FCF Ratio | 20.94 |
| P/OCF Ratio | 11.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.68, with an EV/FCF ratio of 21.98.
| EV / Earnings | 13.84 |
| EV / Sales | 4.55 |
| EV / EBITDA | 8.68 |
| EV / EBIT | 9.35 |
| EV / FCF | 21.98 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.60.
| Current Ratio | 0.78 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 0.61 |
| Debt / FCF | 1.55 |
| Interest Coverage | 19.21 |
Financial Efficiency
Return on equity (ROE) is 71.46% and return on invested capital (ROIC) is 42.81%.
| Return on Equity (ROE) | 71.46% |
| Return on Assets (ROA) | 21.11% |
| Return on Invested Capital (ROIC) | 42.81% |
| Return on Capital Employed (ROCE) | 55.29% |
| Revenue Per Employee | $640,996 |
| Profits Per Employee | $210,765 |
| Employee Count | 77,349 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.42 billion in taxes.
| Income Tax | 4.42B |
| Effective Tax Rate | 21.33% |
Stock Price Statistics
The stock price has decreased by -53.22% in the last 52 weeks. The beta is 0.35, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -53.22% |
| 50-Day Moving Average | 54.30 |
| 200-Day Moving Average | 65.04 |
| Relative Strength Index (RSI) | 36.75 |
| Average Volume (20 Days) | 18,583,061 |
Short Selling Information
The latest short interest is 28.24 million, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 28.24M |
| Short Previous Month | 31.46M |
| Short % of Shares Out | 0.84% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.28 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $49.58 billion and earned $16.30 billion in profits. Earnings per share was $3.67.
| Revenue | 49.58B |
| Gross Profit | 41.37B |
| Operating Income | 24.14B |
| Pretax Income | 20.72B |
| Net Income | 16.30B |
| EBITDA | 26.00B |
| EBIT | 24.14B |
| Earnings Per Share (EPS) | $3.67 |
Balance Sheet
The company has $5.12 billion in cash and $15.90 billion in debt, giving a net cash position of -$10.78 billion or -$2.43 per share.
| Cash & Cash Equivalents | 5.12B |
| Total Debt | 15.90B |
| Net Cash | -10.78B |
| Net Cash Per Share | -$2.43 |
| Equity (Book Value) | 26.69B |
| Book Value Per Share | 6.01 |
| Working Capital | -8.24B |
Cash Flow
In the last 12 months, operating cash flow was $19.45 billion and capital expenditures -$9.08 billion, giving a free cash flow of $10.27 billion.
| Operating Cash Flow | 19.45B |
| Capital Expenditures | -9.08B |
| Free Cash Flow | 10.27B |
| FCF Per Share | $2.31 |
Margins
Gross margin is 83.44%, with operating and profit margins of 48.69% and 32.88%.
| Gross Margin | 83.44% |
| Operating Margin | 48.69% |
| Pretax Margin | 41.80% |
| Profit Margin | 32.88% |
| EBITDA Margin | 52.44% |
| EBIT Margin | 48.69% |
| FCF Margin | 20.71% |
Dividends & Yields
This stock pays an annual dividend of $1.23, which amounts to a dividend yield of 2.59%.
| Dividend Per Share | $1.23 |
| Dividend Yield | 2.59% |
| Dividend Growth (YoY) | 19.97% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 33.57% |
| Buyback Yield | 0.46% |
| Shareholder Yield | 3.01% |
| Earnings Yield | 7.58% |
| FCF Yield | 4.78% |
Analyst Forecast
The average price target for Novo Nordisk is $60.50, which is 27.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.50 |
| Price Target Difference | 27.23% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 7.37% |
| EPS Growth Forecast (5Y) | 7.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 6.16 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.16 |
| Piotroski F-Score | 4 |